Calprotectine in Spondyloarthritis

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Total Enrollment

190 participants

Study Classification

OBSERVATIONAL

Study Start Date

2022-08-15

Study Completion Date

2024-08-15

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

To date, there are no biomarkers in spondyloarthritis that can differentiate between spondyloarthritis and fibromyalgia or other pathologies. Fecal calprotectin is a biomarker that is increasingly used in inflammatory diseases of the digestive tract. A growing interest in this biomarker is emerging in rheumatology, several publications have focused on its interest in rheumatoid arthritis, highlighting an association between serum calprotectin levels and disease activity. In spondyloarthritis, a few studies seem to show that it could be a marker of disease activity. Although a 2012 study found no difference in serum calprotectin levels between subjects with spondyloarthritis and controls. Still others have shown that it could be a predictive factor of radiological evolution in the same disease key. These data support, despite the questionable results of the Klingberg study, the value of this dosage in spondyloarthritis. The objective of this work is to show that this assay could be useful to differentiate spondyloarthritis from other pathologies with similar clinical presentation such as fibromyalgia. Difficulties classically encountered in common practice in rheumatology

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Seric Calprotectine in Spondyloarthritis

NCT03818958

Spondylarthritis

COMPLETED

French Cohort of Undifferentiated Spondyloarthritis

NCT01648907

EARLY UNDIFFERENTIATED SPONDYLARTHROPATHIES

COMPLETED

Quantification and Characterization of Circulating Epithelial and Endothelial Cells in Gougerot-Sjögren Syndrome, Compared to Systemic Sclerosis

NCT05528809

Primary Gougerot-Sjögren Syndrome Systemic Sclerosis, Diffuse

COMPLETED NA

Conception of a Diagnosis, Prognosis and Therapeutic Decision Tool for Patients With Autoimmunity and Inflammation

NCT04902807

Autoimmune Lymphoproliferative Syndrome Autoimmune Cytopenia Autoimmune Diseases +17 more

RECRUITING

Faecal Calprotectin as a Potential Non-invasive Inflammatory Marker in Pregnancy and Inflammatory Bowel Disease

NCT02778464

Inflammatory Bowel Disease (IBD) Crohn's Disease (CD) Ulcerative Colitis (UC) +1 more

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Spondylarthritis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

active spondyloarthritis

subjects with active spondyloarthritis with a BASDAI greater than 4

NO INTERVENTION

Intervention Type OTHER

no intervention

remission spondyloarthritis

subjects presenting with a remission spondyloarthritis defined by a BASDAI less than 4

NO INTERVENTION

Intervention Type OTHER

no intervention

controls without spondyloarthritis

controls without spondyloarthritis or other chronic inflammatory rheumatism and without fibromyalgia

NO INTERVENTION

Intervention Type OTHER

no intervention

fibromyalgia

subjects with fibromyalgia

NO INTERVENTION

Intervention Type OTHER

no intervention

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

NO INTERVENTION

no intervention

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

Patients in the active line of the rheumatology department with one of the following criteria:

active spondyloarthritis (BASDAI \>4), or spondyloarthritis in low activity (BASDAI\<4), or fibromyalgia without associated inflammatory rheumatism, or healthy subjects (without inflammatory rheumatism and without fibromyalgia. Patients who have not objected to the use of their samples